3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
3
Phase NA
1
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
3
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
ZD4054
×
Genitourinary
×
Clear all
NCT00554229
2016-02-08
ENTHUSE M1
AstraZeneca
Phase 3
Completed
896 enrolled
15 charts
NCT00617669
2012-09-10
ENTHUSE M1C
AstraZeneca
Phase 3
Completed
1,494 enrolled
14 charts
NCT00626548
2012-09-03
ENTHUSE M0
AstraZeneca
Phase 3
Terminated
2,577 enrolled
8 charts